指南与共识胸部肿瘤

AI在英国肺癌筛查随访中评估结节体积倍增时间的验证研究

AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validation.
指南 / 共识 · Eur J Cancer · 2025-11-22

该验证研究纳入UKLS试验710名参与者的939次随访低剂量CT,比较AI与人工阅读者对结节体积倍增时间(VDT)的评估性能,以欧洲专家小组和 histological 结果为参考标准。AI在3个月随访中负性误分类率最低(1/11,9.1%),优于人工阅读者(18.2-63.6%),并在组织学确诊的快速生长癌症中更早识别出VDT≤400天。

要点

  • AI在3个月随访中负性误分类率仅9.1%,低于人工阅读者的18.2-63.6%。
  • AI在组织学确诊癌症中识别VDT≤400天的性能优于人工阅读者。
  • AI对专家小组判为阴性但体积<100mm³的癌症也识别出VDT≤400天。

核心结论

  • 自动化AI系统在随访筛查中展现出较强的VDT评估性能,在组织学确诊癌症的早期快速生长识别上优于人工阅读者,支持其提升风险分层和促进肺癌早检的潜力。

研究设计与样本

  • 验证性研究,纳入UKLS试验710名参与者的939次随访低剂量CT扫描(361次3个月随访和578次12个月随访),由AI和人工阅读者独立评估。

主要发现

  • 与专家小组相比,AI的3个月负性误分类率为1/11(9.1%),人工阅读者为18.2-63.6%。
  • AI的阳性误分类率在3个月时为7.8%(28/361),在12个月时降至0.9%(5/578)。
  • 在9例筛查发现的肺癌中,AI在最早3个月随访时对专家小组判为阳性的全部4例癌症均识别出VDT≤400天,而人工阅读者漏诊或延迟转诊1-3例。
  • AI还对专家小组判为阴性的5例癌症中的3例识别出VDT≤400天,主要因这些结节体积低于100mm³阈值。

关键数值与推荐

  • 阳性发现需转诊定义为随访时最大结节实性成分≥100mm³且VDT≤400天。

临床怎么用

  • AI辅助VDT评估可能帮助在随访筛查中更早识别快速生长的肺癌,优化风险分层和转诊决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To validate an artificial intelligence (AI) software for automated assessment of nodule growth by volume doubling time measurement (VDT) on protocol-mandated follow-up low-dose CT (LDCT) scans from the UK lung cancer screening (UKLS) trial. METHODS: This validation study included 710 UKLS participants with 939 LDCT follow-up scans (361 3-month and 578 12-month). Follow-up scans were assessed independently by both AI and human readers. A positive finding warranting referral was defined as the largest nodule with a solid component ≥ 100 mm3 showing VDT ≤ 400 days at follow-up. Performance was benchmarked against the European expert panel (reference standard) and then the histological outcomes (gold standard). RESULTS: Against the expert panel, AI achieved the lowest 3-month negative misclassification (NM) rate (1/11, 9.1 %), versus human readers (range: 18.2-63.6 %). AI's positive misclassification (PM) rate was initially 7.8 % (28/361) at 3 months but decreased to 0.9 % (5/578) at 12 months. Against histological outcomes of 9 screen-detected lung cancers, AI identified VDT ≤ 400 days in all 4 cancers also deemed positive by the expert panel at the earliest 3-month follow-up, while human readers missed or delayed referrals in 1-3 of these. AI also identified VDT ≤ 400 days in 3 of 5 cancers that the panel classified as negative, primarily due to their sub-threshold volume (<100mm³). CONCLUSIONS: The automated AI system showed strong VDT assessment performance in follow-up screening, outperforming human readers in the early identification of rapid growth in histologically-confirmed cancers, thus supporting its potential to enhance risk stratification and facilitate earlier lung cancer detection.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jiang B, Lancaster HL, Davies MPA, et al. AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validation. Eur J Cancer. 2025. PMID: 41319449. doi:10.1016/j.ejca.2025.116137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。